medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2017, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2017; 33 (2)

Clinical and epidemiological aspects of leukemias

Soares AAL, Campos AI, de Souza RPCDP, Fortes VA, Pereira SVE, Ferreira JMA

Language: English
References: 57
Page: 1-14
PDF size: 106.26 Kb.


ABSTRACT

Leukemia is a group of clonal diseases derived from a single cell with a genetic alteration in bone marrow or peripheral lymphoid tissue, and each type is determined by the specificity of the source cell. The objective of this research was to synthesize studies that characterize the clinical and epidemiological profile of patients with leukemia, the types of treatments used, duration and outcomes for the cases. This study is an integrative review of literature through databases Medical Literature Analysis and Retrieval System Online (MEDLINE), SCOPUS, Cumulative Index to Nursing & Allied Health Literature (CINAHL) and Science Direct. There were 4,274 articles rescued in the initial search, 188 were selected to compose the review sample after applying all the criteria for inclusion and exclusion adopted. Full articles were grouped into four categories, according to the variables of research: (a) more frequent subtypes of leukemia; (b) most widely used treatment; (c) duration of treatment; and (d) endpoint of the cases. It is concluded a prevalence of leukemia in pediatric patients, with a predominance of the subtype Acute Lymphoblastic Leukemia (ALL). In general, the male population is more affected by hematological malignancies. As the therapy is used, each leukemia subtype had its peculiarities regarding the treatment, especially the introduction of imatinib for chronic myeloid leukemia (CML) and prophylactic cranial irradiation for cases of ALL. Chronic leukemia showed higher treatment duration. There was a significant improvement in survival of Acute Myeloid Leukemia, Chronic Lymphoid leukemia, CML and ALL, the latter approximately with 90% cure rate in children.


REFERENCES

  1. Stewart BW, Wild CP. World Cancer Report 2014. Lyon (FR): IARC; 2014.

  2. Instituto Nacional do Câncer. Coordenação de Prevenção e Vigilância. Estimativa 2016: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2016.

  3. Rêgo MAV, Fonseca AA. Mortality Trends from Leukemia in Salvador - Brazil, 1980 to 2012. Rev Bras Cancerol. 2015; 61(4):325-34.

  4. Silva DS, Mattos IE, Teixeira LR. Mortality Trends from Leukemia and Lymphomas in People with less than 20 Years, Brazil. Rev Bras Cancerol. 2013;59(2):165-73.

  5. Hoffbrand AV, Moss PAH. Fundamentos em hematologia. Porto Alegre: Artmed; 2013.

  6. Cabral SNS, Santos SL, Beltrão AB, Augusto LGS. Baseline of acute lymphocytic leukemia for surveillance of environmental health on the oil refinery area of the State of Pernambuco, Brazil, 2004 to 2008. Epidemiol Serv Saúde. 2012 Dez;21(4):601-8.

  7. Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs. 2005 Dec; 52(5):546-53.

  8. Knox-Macaulay HHM, Brown LC. Descriptive epidemiology of de novo acute leukaemia in the Sultanate of Oman. Leuk Res. 2000 Jul;24(7):589-94.

  9. Coebergh JW, Reedijk AM, Vries E, Martos C, Jakab Z, Steliarova-Foucher E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978- 1997. Report from the Automated Childhood Cancer Information System Project. Eur J Cancer. 2006 Sept;42(13):2019-36.

  10. Rego EM, Garcia AB, Viana SR, Falcão RP. Characterization of acute lymphoblastic leukemia subtypes in Brazilian patients. Leuk Res. 1996 Apr;20(4):349-55.

  11. Silva FA, Reis RS, Santos MO, Luiz RR, Oliveira MSP. Evaluation of childhood acute leukemia incidence and underreporting in Brazil by capture-recapture methodology. Cancer Epidemiol. 2009 Dec;33(6):403-5.

  12. Al-Bahar S, Pandita R, Al-Muhannaha A, Al-Bahar E. The epidemiology of leukemia in Kuwait. Leuk Res. 1994 Apr;18(4):251-5.

  13. Sayers GM, Rip MR, Jacobs P, Klopper JM, Karabus CD, Rosenstrauch WJ, et al. Epidemiology of acute leukaemia in the Cape Province of South Africa. Leuk Res. 1992 Oct;16(10):961-6.

  14. Bekadja MA, Hamladjib RM, Belhani M, Ardjoun FZ, Abad MT, Touhami H, et al. A population-based study of the epidemiology and clinical features of adults with acute myeloid leukemia in Algeria: report on behalf of the Algerian Acute Leukemia Study Group. Hematol Oncol Stem Cell Ther. 2011;4(4):161-6.

  15. Van den Broeka EC, Katerb AP, Van de Schans SAM, Karim-Kos HE, Janssen- Heijnen ML, Peters WG, et al. Chronic Lymphocytic Leukaemia in the Netherlands: Trends in incidence, treatment and survival, 1989-2008. Eur J Cancer. 2012 Apr;48(6):889-95.

  16. Healeya R, Patela JL, Koninga L, Naugler C. Incidence of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis in Calgary, Alberta, Canada. Leuk Res. 2015 Apr;39(4):429-34.

  17. Shenoy PJ, Malik N, Sinha R, Nooka A, Nastoupil LJ, Smith M, et al. Racial Differences in the Presentation and Outcomes of Chronic Lymphocytic Leukemia and Variants in the United States. Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):498-06.

  18. Maynadiéa M, Troussard X. Épidémiologie des leucémies aiguës. RFL. 2015;2015(471);29-33.

  19. Shi R, Munker R. Survival of patients with mixed phenotype acute leukemias: A large population-based study. Leuk Res. 2015 Jun;39(6):606-16.

  20. Ruiz-Argüelles GJ, Cantú-Rodríguez OG, Gómez-Almaguer D, Cortés-Franco J, Góngora-Biachi RA, Pizzuto J et al. Hairy cell leukemia is infrequent in Mexico and has a geographic distribution. Am J Hematol. 1996 Aug;52(4):316-8.

  21. Paltiel O, Adler B, Barchana M, Dann EJ. A population-based study of hairy cell leukemia in Israel. Eur J Haematol. 2006 Nov;77(5):372-7.

  22. Nirina MOMH, Rakotoarivelo ZL, Ntoezara A, Rasolonjatovo AS, RakotoAlson AO, Rasamindrakotroka A. Epidemiology and diagnosis of acute leukemia in Ravoahangy Andrianavalona hospital Antananarivo Madagascar. African J Cancer. 2015;7:186-9.

  23. Gangatharan SA, Grove CS, P'ng S, O'Reilly J, Joske D, Leahy MF, et al. Acute myeloid leukaemia in Western Australia 1991-2005: a retrospective population-based study of 898 patients regarding epidemiology, cytogenetics, treatment and outcome. Intern Med J. 2013 Aug;43(8):903-11.

  24. Fermo VC, Radünz V, Rosa LM, Marinho MM. Profissionals' attitudes for patient safety culture in units of bone marrow transplantation. Rev Gaúcha Enferm. 2016;37(1):1-9.

  25. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiationbased conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006 Jan;24(3):444-53.

  26. Nagler A, Labopin M, Gorin NC, Ferrara F, Sanz MA, Wu D, et al. Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the acute leukemia working party of the european group for blood and marrow transplantation. Haematologica. 2014 Aug;99(8):1380-6.

  27. Bassi SC, Rego EM. Molecular basis for the diagnosis and treatment of acute promyelocytic leucemia. Rev Bras Hematol Hemoter. 2012;34(2):134-9.

  28. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94(10):3315-24.

  29. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19(18):3852-60.

  30. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, et al. Arsenic trioxidemediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000;60(11):3065-71.

  31. Perkins C, Kim CN, Fang G, Bhalla KN . Arsenic induces apoptosis of multidrugresistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood. 2000;95(3):1014-22.

  32. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277(19):16639-47.

  33. Henk HJ, Woloj M, Shapiro M, Whiteley J. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States. Clin Ther. 2015 Jan;37(1):124-33.

  34. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25(7):793-8.

  35. Panovská A, Doubek M, Brychtová Y, Mayer J. Chronic Lymphocytic Leukemia and Focusing on Epidemiology and Management in Everyday Hematologic Practice: Recent Data From the Czech Leukemia Study Group for Life (CELL). Clin Lymphoma Myeloma Leuk. 2010;10(4):297-300.

  36. Knauf W, Abenhardt W, Dörfel S, Meyer D, Grugel R, Münz M, et al. Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms. Hematol Oncol. 2015 Mar;33(1):15-22.

  37. Guest JF, Smith H, Sladkevicius E, Jackson G. Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom. Clin Ther. 2009;31:2398-415.

  38. Haupt R, Novakovic B, Fears TR, Byrne J, Robinson LL, Tucker MA et al. Can protocol-specified doses of chemotherapy and radiotherapy be used as a measure of treatment actually received? A CCG/NIH study on long-term survivors of acute lymphocytic leucemia. J Clin Epidemiol. 1996 Jun;49(6):687-90.

  39. Boguslawska-Jaworska J, Chybicka A, Koscielniak E, Armata J, Ochocka M, Koscielniak U et al. The results of high risk children's acute lymnphoblastic leukemia total therapy. A report from the polish children's leukemia/lymphoma study group. Europ Paediatr Hematol Oncol. 1984;1(1):107-12.

  40. Pui CH, Campana D, Pei D, Bowman P, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. Engl J Med. 2009 Jun;360:2730-41.

  41. Selwood K, Pizer B, Gibson B, Skinner R. Vascular access for daunorubicin during childhood acute lymphoblastic leukaemia induction treatment: A UKCCSG supportive care group and MRC childhood leukaemia working party survey. Eur J Oncol Nurs. 2008 Dec;12(5):476-8.

  42. Call TG, Norman AD, Hanson CA, Achenbach SJ, Kay NE, Zent CS, et al. Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines. Cancer 2014 Jul;120(13):2000-5.

  43. Szerafin L, Jakó J, Riskó F. Prognostic value of absolute monocyte count in chronic lymphocytic leukaemia. Orvosi Hetilap. 2015 Apr;156(15):592-7.

  44. Bow EJ, Gallant G, Williams GJ, Woloschuk D, Shore TB, Rubinger M, et al. Remission induction therapy of untreated acute myeloid leukemia using a noncytarabine- containing regimen of idarubicin, etoposide, and carboplatin. Cancer. 1998;83(7):1344-54.

  45. Shah BK, Ghimire KB. Improved survival among older acute myeloid leukemia patients - a population-based study. Acta Oncol. 2014 Jul;53(7): 935-8.

  46. Lang K, Earle CC, Foster T, Dixon D, Van Gool R, Menzin J. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging. 2005;22(11):943-55.

  47. Hossain J, Xie L, Caywood EH. Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: Evidence from four decades of US population data. Cancer Epidemiol. 2015 Oct;39(5):720-6.

  48. Chihara D, Ito H, Matsuda T, Katanoda K, Shibata A, Saika K, et al. Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S. Oncologist. 2012;17(12):1547-50.

  49. Menzin J, Lang K, Earle CC, Glendenning A. Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis. Drugs Aging. 2004;21(11):737-46.

  50. Rodríguez APG, García EG, Álvarez CF, Huerta AJG, Rodríguez SG. B-chronic lymphocytic leukemia: Epidemiological study and comparison of MDACC and GIMENA pronostic indexes. Med Clin. 2009 Jul;133(5):161-6.

  51. Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood, 2008;111(10):4916-21.

  52. Pulte D, Gondos A, Brenner H. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004. J Natl Cancer Inst. 2008;100(18):1301-9.

  53. Essig S, Li Q, Chen Y, Hitzler J, Leisenring W, Greenberg M, et al. Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort. The Lancet Oncology. 2014 Jun;15(8): 841-51.

  54. Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G, et al. Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer. 2008 Jan;44(2):257-68.

  55. Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Tracey E, et al. Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. JNCI. 2007;99(10):790-800.

  56. Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007 Mar;297(11):1207-15.

  57. Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, et al. Trends in survival of patients with primary plasma cell leukemia: A population-based analysis. Blood. 2014 Aug;124(6):907-12.




2020     |     www.medigraphic.com